RnRMarketResearch.com adds “Psychosis – Pipeline Review, H1 2015” to its store. The report provides an overview of the Psychosis’s therapeutic pipeline.

Dallas, TX -- (SBWire) -- 06/04/2015 --The report "Psychosis – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Psychosis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1 2015 pipeline review of Psychosis with 24 market data tables and 11 figures, spread across 52 pages is available at http://www.rnrmarketresearch.com/ageing-pipeline-review-h1-2015-market-report.html.

Companies discussed in this Psychosis – Pipeline Review, H1 2015 report include Acadia Pharmaceuticals Inc., Evotec AG, Heptares Therapeutics Ltd., Newron Pharmaceuticals S.p.A., Reviva Pharmaceuticals Inc., Sumitomo Dainippon Pharma Co., Ltd.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are Drug to Agonize Muscarinic M1/M4 Receptors for Psychosis and Cognitive Impairment, Drug to Agonize Muscarinic M4 Receptors for Psychosis, NW-3509, pimavanserin tartrate, RP-5063, Small Molecule to Inhibit PDE10a for Schizophrenia and Psychosis, Small Molecules to Activate Sigma Receptor for CNS Disorders, Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=388756 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report includes: Nov 17, 2014: Heptares First-In-Class Selective Muscarinic Agonists Chosen As One Of Top Neuroscience Projects To Watch; Sep 02, 2014: Acadia Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID? (Pimavanserin) for Parkinson's Disease Psychosis; Aug 28, 2014: ACADIA Pharmaceuticals Announces Trade Name NUPLAZID for Pimavanserin; Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting; Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis; May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis; Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis.

This report is complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psychosis and special features on late-stage and discontinued projects.

List of Tables
Number of Products under Development for Psychosis, H1 2015 7
Number of Products under Development for Psychosis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Comparative Analysis by Unknown Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Psychosis - Pipeline by Acadia Pharmaceuticals Inc., H1 2015 17
Psychosis - Pipeline by Evotec AG, H1 2015 18
Psychosis - Pipeline by Heptares Therapeutics Ltd., H1 2015 19
Psychosis - Pipeline by Newron Pharmaceuticals S.p.A., H1 2015 20
Psychosis - Pipeline by Reviva Pharmaceuticals Inc., H1 2015 21
Psychosis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 25
Number of Products by Stage and Mechanism of Action, H1 2015 27
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 29
Psychosis Therapeutics - Recent Pipeline Updates, H1 2015 39
Psychosis - Dormant Projects, H1 2015 45
Psychosis - Discontinued Products, H1 2015 46

List of Figures
Number of Products under Development for Psychosis, H1 2015 7
Number of Products under Development for Psychosis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Top 10 Targets, H1 2015 24
Number of Products by Stage and Top 10 Targets, H1 2015 24
Number of Products by Top 10 Mechanism of Actions, H1 2015 26
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 28
Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Explore more reports on Neurology therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/neurology-therapeutics.

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.